Literature DB >> 12065002

Treating depression: the beyondblue guidelines for treating depression in primary care. "Not so much what you do but that you keep doing it".

Pete M Ellis1, Don A R Smith.   

Abstract

1. Most people with depression will be treated in general practice, either by the GP alone, or (for more serious depression) in partnership with specialist mental health services. 2. Treatment plans should always be based on thorough assessment, including the type, severity and duration of the depressive episode, and any stressors that contributed to the episode. 3. For mild and moderate depression, meta-analysis shows there is little difference in relative effectiveness of treatments, and continuation of therapy is more important than initial treatment choice. 4. The best outcomes are likely when a good therapeutic alliance is formed between a healthcare professional and the patient, and adequate treatment is provided over a long enough period. For pharmacological interventions, treatment should continue for: at least one year for a first episode of depression, and at least two years for repeated episodes or where there are other risk factors for relapse.

Entities:  

Mesh:

Year:  2002        PMID: 12065002

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  10 in total

1.  Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis.

Authors:  Bruce Arroll; Steve Macgillivray; Simon Ogston; Ian Reid; Frank Sullivan; Brian Williams; Iain Crombie
Journal:  Ann Fam Med       Date:  2005 Sep-Oct       Impact factor: 5.166

2.  New users of antidepressant medications: first episode duration and predictors of discontinuation.

Authors:  Christine Y Lu; Elizabeth Roughead
Journal:  Eur J Clin Pharmacol       Date:  2011-06-29       Impact factor: 2.953

Review 3.  Overuse of antidepressant drugs for the treatment of depression.

Authors:  Jon Jureidini; Anne Tonkin
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 4.  Treatment of recurrent depression: a sequential psychotherapeutic and psychopharmacological approach.

Authors:  Giovanni A Fava; Chiara Ruini; Nicoletta Sonino
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

5.  Health e-cards as a means of encouraging help seeking for depression among young adults: randomized controlled trial.

Authors:  Daniel L Costin; Andrew J Mackinnon; Kathleen M Griffiths; Philip J Batterham; Anthony J Bennett; Kylie Bennett; Helen Christensen
Journal:  J Med Internet Res       Date:  2009-10-22       Impact factor: 5.428

6.  Repetitive transcranial magnetic stimulation for the treatment of major depressive disorder: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2004-06-01

7.  General Practitioners' opinions on their practice in mental health and their collaboration with mental health professionals.

Authors:  Nadia Younes; Isabelle Gasquet; Pierre Gaudebout; Marie-Pierre Chaillet; Viviane Kovess; Bruno Falissard; Marie-Christine Hardy Bayle
Journal:  BMC Fam Pract       Date:  2005-05-02       Impact factor: 2.497

8.  The Sleep Or Mood Novel Adjunctive therapy (SOMNA) trial: a study protocol for a randomised controlled trial evaluating an internet-delivered cognitive behavioural therapy program for insomnia on outcomes of standard treatment for depression in men.

Authors:  Nicole L Cockayne; Helen M Christensen; Kathleen M Griffiths; Sharon L Naismith; Ian B Hickie; Frances P Thorndike; Lee M Ritterband; Nick S Glozier
Journal:  BMC Psychiatry       Date:  2015-02-05       Impact factor: 3.630

Review 9.  Evidence based psychosocial interventions in substance use.

Authors:  Sonali Jhanjee
Journal:  Indian J Psychol Med       Date:  2014-04

10.  GPs' use of problem solving therapy for depression: a qualitative study of barriers to and enablers of evidence based care.

Authors:  David Pierce; Jane Gunn
Journal:  BMC Fam Pract       Date:  2007-04-25       Impact factor: 2.497

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.